18.27
1.95%
0.405
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.86
Offen:
$17.96
24-Stunden-Volumen:
58,849
Relative Volume:
0.03
Marktkapitalisierung:
$1.55B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-4.0409
EPS:
-4.52
Netto-Cashflow:
$-369.41M
1W Leistung:
-1.42%
1M Leistung:
+0.59%
6M Leistung:
+175.45%
1J Leistung:
+222.26%
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
TVTX | 18.36 | 1.55B | 203.45M | -351.45M | -369.41M | -4.52 |
VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
2023-11-20 | Eingeleitet | Citigroup | Neutral |
2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
2023-07-21 | Eingeleitet | JP Morgan | Overweight |
2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
2023-05-22 | Eingeleitet | TD Cowen | Outperform |
2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
2023-03-01 | Eingeleitet | Guggenheim | Buy |
2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
2022-12-14 | Eingeleitet | Stifel | Hold |
2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Oppenheimer & Co. Inc. Acquires New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices
Travere: Q3 Earnings Snapshot - AOL
Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
When (TVTX) Moves Investors should Listen - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail
Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times
3 Under-the-Radar Healthcare Companies - sharewise
3 Under-the-Radar Healthcare Companies to Watch - MarketBeat
Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat
TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India
Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP
Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga
Travere Therapeutics plans public stock offering - Investing.com India
Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan
Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):